Literature DB >> 11761430

Acromegaly: historical perspectives and current therapy.

J A Jane1, K Thapar, E R Laws.   

Abstract

Soon after the initial description of acromegaly in the late 19th century, neurosurgeons performed the first operative procedures for the disease. Transcranial procedures eventually yielded to the transsphenoidal approach. Reasonably effective medical therapy was introduced in the 1970s and pharmacological progress continues to be realized. It is now recognized that excess growth hormone is associated with significant morbidity and mortality and that biochemical remission improves outcome. Although medical and radiation treatments offer useful adjuncts, surgery provides optimal results.

Entities:  

Mesh:

Year:  2001        PMID: 11761430     DOI: 10.1023/a:1012949214960

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  87 in total

1.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

2.  III. Partial Hypophysectomy for Acromegaly: With Remarks on the Function of the Hypophysis.

Authors:  H Cushing
Journal:  Ann Surg       Date:  1909-12       Impact factor: 12.969

Review 3.  Growth-hormone and prolactin excess.

Authors:  A Colao; G Lombardi
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

4.  Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

Authors:  A Colao; P Marzullo; D Ferone; V Marinò; R Pivonello; C Di Somma; A Di Sarno; A Giaccio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 5.  Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors:  J C Gillis; S Noble; K L Goa
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

6.  Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

Authors:  R Cozzi; R Attanasio; M Barausse; D Dallabonzana; P Orlandi; N Da Re; V Branca; G Oppizzi; D Gelli
Journal:  Eur J Endocrinol       Date:  1998-11       Impact factor: 6.664

7.  Conventional supervoltage irradiation is an effective treatment for acromegaly.

Authors:  R C Eastman; P Gorden; J Roth
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

8.  Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses.

Authors:  C A Jaffe; R D Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.

Authors:  B Merola; A Cittadini; A Colao; D Ferone; S Fazio; D Sabatini; B Biondi; L Saccá; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

View more
  3 in total

1.  Simultaneous symptomatic Rathke's cleft cyst and GH secreting pituitary adenoma: a case report.

Authors:  Lucas J Bader; Kawanaa D Carter; Richard E Latchaw; William G Ellis; Jason A Wexler; Joseph C Watson
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

2.  Governor Pio Pico, the monster of California...no more: lessons in neuroendocrinology.

Authors:  Ivan S Login; Jessica Login
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

Review 3.  Multiple endocrine neoplasia type I.

Authors:  Rasa Zarnegar; Laurent Brunaud; Orlo H Clark
Journal:  Curr Treat Options Oncol       Date:  2002-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.